Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...
pharmaphorum16h
Competition for Neurocrine as Gocovri picks up new Parkinson's indication
The new indication brings the drug into direct competition with Ongentys from rival Neurocrine Biosciences, which was approved for the same use last year. Adamas noted that Gocovri (amantadine ...
University of Geneva20h
3 avril 2025: Pr Amin Rostami-Hodjegan
Pr Amin Rostami-Hodjegan 12H30 CMU - AUDITOIRE Müller (A250) suivi d'un apéritif. Hôtes: Pr Youssef Daali & Pr Pierre FONTANA Centre facultaire d’investigation ...